DC4U exploits its GlycoDCTM targeting technology as a platform for applications in oncology, allergy, vaccines and auto-immune diseases. Our technology and products are well protected by a number of patents, covering applications in both immunity as well as tolerance induction.  Our business strategy is to offer early stage business and partnering options to the food- and pharmaceutical industry, including licensing and co-development.

Our prospective clients operate in a highly competitive R&D environment. GlycoDCTM technology will strengthen their competitive advantage by providing them a unique position in the development of  both stimulating and suppressive glycan-antigen based products and therapeutics. We aim for early stage cooperation with these companies.